ReviewNature reviews. Gastroenterology & hepatology2015
Precision prevention of oesophageal adenocarcinoma.
Review in Nature reviews. Gastroenterology & hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma.Gastroenterology · 2020Pooled it
- Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020Guideline
- Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.Lancet (London, England) · 2020Trial
- Trial
- Trial
- Comparison of Invasive Interventions for Halting the Progression of Barrett's Esophagus.Cureus · 2026Review
- Evaluating Cost-Effectiveness of 85 Endoscopic Surveillance Strategies of Nondysplastic Barrett's Esophagus.Journal of gastroenterology and hepatology · 2026Article
- Endoscopic Screening of Barrett's Esophagus.Gastrointestinal endoscopy clinics of North America · 2026Review
- The SOX4-Semaphorin3C axis promotes esophageal adenocarcinoma progression.Cancer letters · 2025Article
- Swallowable expandable fibrous capsules for nonendoscopic sampling of esophageal cells.Science advances · 2025Article
- Strategies to prevent Barrett's esophagus associated esophageal adenocarcinoma.World journal of gastroenterology · 2025Review
- Microfluidic Biochip-Based Multiplexed Profiling of Small Extracellular Vesicles Proteins Integrated with Machine Learning for Early Disease Diagnosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Computing lifetime incidence of esophageal adenocarcinoma and age-specific prevalence of Barrett's esophagus.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- Current status and perspectives of esophageal cancer: a comprehensive review.Cancer communications (London, England) · 2025Review
- Liquid biopsy to identify Barrett's oesophagus, dysplasia and oesophageal adenocarcinoma: theGut · 2025Article
- A Systematic Review of Risk Prediction Models for Esophageal Adenocarcinoma in the General Population.Gastro hep advances · 2025Review
- Cost-effective identification of Barrett's esophagus in the community: A first step towards screening.Journal of gastroenterology and hepatology · 2024Article
- Unraveling the causality between gastroesophageal reflux disease and increased cancer risk: evidence from the UK Biobank and GWAS consortia.BMC medicine · 2024Article
- Advances in Screening for Barrett Esophagus and Esophageal Adenocarcinoma.Mayo Clinic proceedings · 2024Review
- Prevalence and Predictors of Barrett's Esophagus After Negative Initial Endoscopy: Analysis From Two National Databases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The incidence of oesophageal adenocarcinoma has risen rapidly over the past four decades. Unfortunately, treatments have not kept pace; unless their cancer is identified at a very early stage, most patients will not survive a year after diagnosis. The beginnings of this widespread problem were first recognized over 25 years ago, yet rates have continued to rise against a backdrop of much improved understanding and management of oesophageal adenocarcinoma. We estimate that only ∼7% of the 10,000 cases of oesophageal adenocarcinoma diagnosed annually in the USA are identified through current approaches to cancer control, and trace pathways by which the remaining 93% are 'lost'. On the basis of emerging data on aetiology and predictive factors, together with new diagnostic tools, we suggest a five-tier strategy for prevention and control that begins with a wide population base and triages individuals into progressively higher risk strata, each with risk-appropriate prevention, screening and treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.